UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure
Cancer Chemotherapy and Pharmacology · 2024
DOI: 10.1007/s00280-023-04634-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Vikram Malhi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, CA, 650-484-6516, USA. Hauptthemen laut MEDLINE: Glucuronosyltransferase, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F. Hoffmann-La Roche.
Abstract (Originalsprache)
Purpose
Giredestrant is a potent, orally bioavailable, small-molecule selective estrogen receptor antagonist and degrader (SERD) that is being developed for the treatment of patients with estrogen receptor (ER)-positive breast cancer. In vitro, giredestrant was primarily metabolized by UGT1A4. The goal of this study was to investigate if UGT1A4 polymorphism had a clinically relevant impact on giredestrant exposure.
Methods
Genotyping and pharmacokinetic data were obtained from 118 and 61 patients in two clinical studies, GO39932 [NCT03332797] and acelERA Breast Cancer [NCT04576455], respectively.
Results
The overall allelic frequencies of UGT1A4*2 and UGT1A4*3 were 3.3% and 11%, respectively. Giredestrant exposure was consistent between patients with wild-type UGT1A4 and UGT1A4*2 and *3 polymorphisms, with no clinically relevant difference observed. In addition, haplotype analysis indicated that no other UGT1A4 variants were significantly associated with giredestrant exposure.
Conclusion
Therefore, this study indicates that UGT1A4 polymorphism status is unlikely a clinically relevant factor to impact giredestrant exposure and giredestrant can be administered at the same dose level regardless of patients’ UGT1A4 polymorphism status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, CA, 650-484-6516, USA.
- Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.
- Product Development Clinical Operations, Genentech, Inc., South San Francisco, CA, USA.
- Oncology Bioinformatics, Genentech, Inc., South San Francisco, CA, USA.
- Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA.
- Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, CA, 650-484-6516, USA. yuj59@gene.com.
ORCID-Profile: Jiajie Yu
Förderung
- F. Hoffmann-La Roche
Zitieren
APA
Malhi, V., Nowicka, M., Chen, Y. C., Agarwal, P., Waldvogel, M., Lien, Y. T. K., Hafner, M., Perez-Moreno, P., Moore, H. M., & Yu, J. (2024). UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04634-4
Vancouver
Malhi V, Nowicka M, Chen YC, Agarwal P, Waldvogel M, Lien YTK, et al. UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-023-04634-4
BibTeX
@article{Malhi2024,
author = {Malhi, Vikram and Nowicka, Malgorzata and Chen, Ya-Chi and Agarwal, Priya and Waldvogel, Marie and Lien, Yi Ting Kayla and Hafner, Marc and Perez-Moreno, Pablo and Moore, Heather M and Yu, Jiajie},
title = {UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
doi = {10.1007/s00280-023-04634-4}
}
EUVIMED